Medical errors complicate an already tenuous situation, further damaging a patients health
Moreover, while placebo-controlled clinical trials have found tirzepatides weight loss to be most favorable, a formal head-to-head study involving those with obesity is still in progress
The New England journal of medicine , 371 (7), 624634
Occurs with both routes but is more common with SubQ administration, particularly when the same 12 cm area is used repeatedly without adequate site rotation
Providers should weigh discontinuation decisions carefully in these populations and discuss restart plans proactively if stopping is unavoidable
In addition to the FDAs scrutiny of outsourcing facilities and compounders in the GLP-1 space, the FDA has expressed concerns over the use of unapproved GLP-1 drugs for weight loss, 2 including dosing concerns with compounded semaglutide and tirzepatide products, salt forms that should not be used to compound semaglutide, use of retatrutide in compounding, and adverse events related to compounded versions of semaglutide and tirzepatide, among others
